Probe into Tomorrow’s Cancer Cure

CARsgen therapeutics is a clinical-stage immunotherapy company with a focus to develop and commercialize novel chimeric antigen receptor T-cell (CAR-T) therapeutics. The main goal is to harness our propriety and state-of-the-art CAR-T therapy to fight against tumor with a perspective to cure cancer, improving people’s life quality and reducing associated suffering.
Gathered by a group of world-class scientists, CARsgen has developed World’s first-in-class CAR-T candidate for hepatocellular carcinoma and China’s exclusive candidate for glioblastoma multiforme.
First-human-dose tests have been carefully operated. Safety is well addressed and efficacy depends on longer observations to determine. With continuous and further dedications in research and development, CARsgen aims to develop a cross-function and visionary company to lead CAR-T developments around the world.